Olympus Corp. (JP:7733)
:7733
Want to see JP:7733 full AI Analyst Report?
Top Page
Olympus
(7733)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥1,944.00
▲(22.77% Upside)
Action:Reiterated
Date:06/11/26
The score is driven primarily by solid fundamentals (steady revenue growth, high gross margins, and a strengthened balance sheet), tempered by 2026 margin compression and weaker/volatile cash flow. Technicals are moderately supportive but not strong, and valuation looks somewhat expensive (P/E ~28) with only a modest dividend yield.
Positive Factors
Steady revenue growth
Sustained multi-year top-line growth indicates durable demand for Olympus' endoscopy systems and consumables, supporting a growing installed base and recurring revenue streams. This stability underpins long-term investment in product refresh cycles and service contracts.
Negative Factors
2026 margin compression
A significant drop in net margin signals cost pressure, mix shifts, or higher operating expenses that compress earnings power. If structural, reduced margins limit reinvestment capacity, weaken free cash generation, and constrain long-term profitability resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
Sustained multi-year top-line growth indicates durable demand for Olympus' endoscopy systems and consumables, supporting a growing installed base and recurring revenue streams. This stability underpins long-term investment in product refresh cycles and service contracts.
Read all positive factors
Olympus (7733) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥1.87T
Dividend Yield1.01%
Average Volume (3M)3.67M
Price to Earnings (P/E)27.6
Beta (1Y)0.83
Revenue Growth1.34%
EPS Growth-40.50%
CountryJP
Employees28,838
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)61.37
Shares Outstanding1,114,485,700
10 Day Avg. Volume4,971,740
30 Day Avg. Volume3,665,053
Financial Highlights & Ratios
PEG Ratio-0.60
Price to Book (P/B)2.04
Price to Sales (P/S)1.64
P/FCF Ratio36.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,175.00Price Target Upside37.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)89.2
Revenue Forecast (FY)¥1.06T
Olympus Business Overview & Revenue Model
Company Description
Olympus Corporation, a global enterprise headquartered in Tokyo, Japan, manufactures and distributes high-precision machinery and instrumentation worldwide. The company, originally established in 1919 as Olympus Optical Co., Ltd., adopted its curr...
How the Company Makes Money
Olympus makes money mainly by selling medical devices and systems—particularly endoscopes and endoscopic imaging platforms—used by hospitals and clinics for diagnostic and therapeutic procedures. Revenue is generated from (1) capital equipment sal...
Olympus Earnings Call Summary
Earnings Call Date:Feb 13, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Negative
The call presented a mix of significant near-term challenges—most notably product ship holds, FDA observations, one-off costs that reduced gross margin and a 2% revenue guidance downgrade—balanced against clear remediation plans, leadership actions, a majority of held products already released (70%), an asserted China recovery (≈5–6%), maintained midterm targets and a commitment to >100 bps margin expansion beginning FY2027. Near-term financial impact is material, but management articulated specific corrective actions and kept long-term targets unchanged.Positive Updates
Midterm Targets and Margin Commitment Maintained
Management reaffirmed the midterm 3/4/5 plan targets: mid-single-digit revenue growth and a 20%+ operating margin long-term goal, and committed to delivering more than 100 basis points of margin expansion beginning in FY2027.
Negative Updates
Revenue Guidance Revised Down 2% (Constant Currency)
Management revised full-year revenue guidance down by approximately 2% on a constant-currency basis, citing ship holds and execution issues impacting SIS and portions of GI (U.S.).
Read all updates
Q3-2026 Updates
Positive
Negative
Midterm Targets and Margin Commitment Maintained
Management reaffirmed the midterm 3/4/5 plan targets: mid-single-digit revenue growth and a 20%+ operating margin long-term goal, and committed to delivering more than 100 basis points of margin expansion beginning in FY2027.
Read all positive updates
Company Guidance
Management revised FY26 revenue guidance down ~2% on a constant‑currency basis and attributed the cut largely to one‑off FDA‑related ship‑holds and remediation: they cited about JPY 9 billion tied to ship‑hold actions, expect roughly JPY 18 billion of lost revenue in Q4 from held products, have released ~70% of affected products with ~30% still remediating, and expect the remaining holds to be resolved in Q4. They disclosed a JPY 31 billion restructuring/headcount charge (up from an initial JPY 12 billion) related to a net reduction of ~2,000 positions (≈90% charged this year, 10% next year) while keeping expected cost savings of about JPY 24 billion intact. Management said the gross‑margin hit was one‑off (COGS increases from field corrective actions, disposals and recalls), will largely absorb remediation costs in SG&A, does not expect additional ship‑holds, will present guidance as ranges going forward, reaffirmed commitment to >100 basis‑points of annual margin expansion from FY‑27 and to mid‑single‑digit revenue growth and a 20%+ operating margin long term, and noted China is beginning to recover (+5–6% after prior double‑digit declines) while inspections affected GI‑ET, urology, respiratory and surgical portfolios.Olympus Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
58
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.01T | 997.33B | 925.75B | 881.92B | 750.12B |
| Gross Profit | 654.09B | 649.29B | 583.63B | 562.70B | 475.99B |
| EBITDA | 170.51B | 230.35B | 115.36B | 255.07B | 211.46B |
| Net Income | 68.17B | 117.86B | 242.57B | 143.43B | 115.74B |
Balance Sheet | |||||
| Total Assets | 1.54T | 1.43T | 1.53T | 1.51T | 1.36T |
| Cash, Cash Equivalents and Short-Term Investments | 188.04B | 252.53B | 340.93B | 169.33B | 302.57B |
| Total Debt | 239.58B | 291.57B | 360.56B | 397.22B | 451.14B |
| Total Liabilities | 725.12B | 679.89B | 775.56B | 865.71B | 844.60B |
| Stockholders Equity | 812.04B | 751.73B | 757.19B | 640.09B | 510.17B |
Cash Flow | |||||
| Free Cash Flow | 45.03B | 144.46B | -4.06B | 50.92B | 128.04B |
| Operating Cash Flow | 100.58B | 190.46B | 42.37B | 98.49B | 169.73B |
| Investing Cash Flow | -87.41B | -65.47B | 357.07B | -58.41B | -71.02B |
| Financing Cash Flow | -87.63B | -211.54B | -273.09B | -143.18B | -40.67B |
Olympus Technical Analysis
Negative
1583.50
Price Trends
1676.11
Positive
1636.97
Positive
1764.96
Negative
Market Momentum
25.86
Positive
44.67
Neutral
10.46
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7733, the sentiment is Negative. The current price of 1583.5 is below the 20-day moving average (MA) of 1815.25, below the 50-day MA of 1676.11, and below the 200-day MA of 1764.96, indicating a neutral trend. The MACD of 25.86 indicates Positive momentum. The RSI at 44.67 is Neutral, neither overbought nor oversold. The STOCH value of 10.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7733.
Olympus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥964.45B | 31.49 | 11.64% | 0.82% | 15.13% | 196.11% | |
71 Outperform | ¥3.25T | 23.87 | 8.98% | 1.22% | 9.24% | 16.68% | |
71 Outperform | ¥166.00B | 26.24 | ― | 2.73% | 6.29% | -7.19% | |
66 Neutral | ¥1.87T | 27.62 | 11.34% | 1.01% | 1.34% | -40.50% | |
57 Neutral | ¥876.48B | 24.57 | 9.38% | 1.88% | -1.70% | -33.90% | |
54 Neutral | ¥275.39B | 20.39 | 4.38% | 2.03% | 2.47% | 164.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7733
Olympus
1,703.00
-168.57
-9.01%
JP:4543
Terumo
2,199.50
-362.93
-14.16%
JP:7747
Asahi Intecc Co
3,635.00
1,367.87
60.33%
JP:8086
Nipro
1,688.50
452.34
36.59%
JP:6869
Sysmex
1,405.50
-1,013.95
-41.91%
JP:7730
Mani, Inc.
1,685.00
537.01
46.78%
Olympus Corporate Events
Olympus Completes $270 Million Acquisition of Israel’s BioProtect
Jun 2, 2026
Olympus has completed the acquisition of Israel-based BioProtect Ltd., a developer and manufacturer of biodegradable rectal spacer balloons, for around 270 million dollars, giving it 100% of the company’s voting rights. The deal strengthens ...
Olympus to Buy Israel’s BioProtect in Push Into Prostate Cancer Care
May 26, 2026
Olympus has agreed to acquire Israel-based BioProtect Ltd., a developer of biodegradable implant technologies that protect healthy tissue during radiation therapy and surgery, for about $270 million, making it a wholly owned subsidiary. The deal e...
Olympus Completes ¥60 Billion Share Buyback and Sets 2027 Cancellation
May 13, 2026
Olympus has completed a major share repurchase via the Tokyo Stock Exchange’s ToSTNeT-3 system, buying back 38,948,300 common shares for roughly JPY 60 billion, effectively reaching the full monetary limit authorized by its board. This move ...
Olympus Launches ¥60 Billion Share Buyback via ToSTNeT-3
May 12, 2026
Olympus Corporation’s board has approved a share repurchase program and set the specific terms for an initial transaction using the Tokyo Stock Exchange’s ToSTNeT-3 off-auction system. The company plans to buy back up to 38,948,300 com...
Olympus Launches ¥60 Billion Share Buyback and Plans Treasury Share Cancellation
May 12, 2026
Olympus Corporation’s board has approved a share repurchase program of up to 46 million common shares, representing about 4.18% of its outstanding stock, for a maximum total of ¥60 billion. The buyback, to be executed between May 13, 20...
Olympus Nears Target in Global Workforce Optimization Drive
May 12, 2026
Olympus is advancing a global personnel optimization program under its new corporate strategy, targeting workforce reductions across the parent company and group entities. The initiative applies to employees meeting set criteria and is scheduled f...
Olympus Beats FY2026 Guidance on Strong GI Solutions and Asset Gains
May 12, 2026
Olympus reported that its fiscal 2026 results modestly exceeded prior guidance, with revenue rising to ¥1.01 trillion and all major profit indicators coming in above earlier forecasts. The company noted that these figures reflect continuing o...
Olympus Restructures Medical Segments as Profit Slips Despite Steady Revenue
May 12, 2026
Olympus reported consolidated results for the fiscal year ended March 31, 2026, showing revenue of about ¥1.01 trillion from continuing operations and a sharp year-on-year decline in operating profit and net income, as margins compressed desp...
Olympus Issues FY2026 Results and FY2027 Outlook with Cautionary Guidance
May 12, 2026
Olympus released its consolidated financial results for fiscal year 2026 and issued full-year guidance for fiscal 2027, outlining management’s current views and expectations for the business. The company emphasized that these results and pro...
Olympus Profit Slumps Despite Higher Revenue as Portfolio Shift Continues
May 12, 2026
Olympus reported fiscal 2026 revenue of ¥1.01 trillion, up 1.3% year on year, but operating profit from continuing operations fell 40.2% to ¥97.1 billion, with adjusted operating profit down 24%. Profit attributable to owners of the pare...
Olympus Revamps Board With Veteran Global Healthcare Executives
Mar 27, 2026
Olympus has announced proposed changes to its Board of Directors, adding two seasoned healthcare executives as outside director candidates, subject to shareholder approval at the June 2026 general meeting. The company has nominated Jean-Luc Butel,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.